Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Maxim Group restated a “hold” rating on shares of Galmed Pharmaceuticals in a report on Friday, April 4th.

Galmed Pharmaceuticals Price Performance

Shares of NASDAQ:GLMD opened at $1.32 on Friday. Galmed Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $23.80. The business’s 50-day moving average is $2.02 and its 200-day moving average is $2.90. The company has a market capitalization of $2.18 million, a price-to-earnings ratio of -0.08 and a beta of 0.70.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.